StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3086% above fair value
$7.48−0.05 (-0.66%)

Close on Nov 18, 2026Market cap $3.39BP/E –Yield –

Iovance Biotherapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Iovance Biotherapeutics's revenue for the twelve months ending Jun 30, 2026 was $324.97M, up 34.5% year over year. For fiscal 2025 it was $263.50M, up 60.6% from the year before. The highest annual figure on record is $263.50M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$263.50M+60.6%
FY2024Dec 31, 2024$164.07M+13699.0%
FY2023Dec 31, 2023$1.19M–
FY2018Dec 31, 2018$0–
FY2017Dec 31, 2017$0–
FY2016Dec 31, 2016$0–
FY2015Dec 31, 2015$0–
FY2014Dec 31, 2014$0–
FY2013Dec 31, 2013$0–
FY2012Dec 31, 2012$0–
FY2011Dec 31, 2011$0–
FY2010Dec 31, 2010$0–
FY2009Dec 31, 2009$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$99.31M+65.7%
Q1 FY2026Mar 31, 2026$71.43M+44.8%
Q4 FY2025Dec 31, 2025$86.77M+17.7%
Q3 FY2025Sep 30, 2025$67.46M+15.2%
Q2 FY2025Jun 30, 2025$59.95M+92.7%
Q1 FY2025Mar 31, 2025$49.32M+6798.5%
Q4 FY2024Dec 31, 2024$73.69M+15189.2%
Q3 FY2024Sep 30, 2024$58.56M+12385.1%
Q2 FY2024Jun 30, 2024$31.11M+12969.7%
Q1 FY2024Mar 31, 2024$715.00K–
Q4 FY2023Dec 31, 2023$482.00K–
Q3 FY2023Sep 30, 2023$469.00K–
Q2 FY2023Jun 30, 2023$238.00K–
Q1 FY2019Mar 31, 2019$0–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0–
Q1 FY2018Mar 31, 2018$0–
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$0–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$0–
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Sep 30, 2016$0–

More Iovance Biotherapeutics figures

See a number that looks wrong?